Corporate News
Medexus (MDP.TO) Holds Steady Amid Market Fluctuations
On Wednesday, 21 November 2026, Medexus Pharmaceuticals Inc. (MDP.TO) closed its trading session at an unchanged price, recording a 0 % change over the 24‑hour period that ended at 02:11 AM Central Europe time. The Canadian‑listed shares trade at roughly CAD 4.92 on major exchanges, and the company’s current supply of shares stands at 31.4 million.
Medexus’ market capitalisation sits at CAD 153 million, a figure that reflects the company’s valuation in the broader health‑care sector. Over the last 24 hours, approximately CAD 54 000 worth of Medexus stock has moved on the exchanges, a modest volume compared with the company’s overall liquidity. Since the end of last month, the share price has slipped by 4.72 %, indicating a slight downward trend in investor sentiment.
Key technical metrics paint a clear picture of the stock’s recent trajectory. The simple moving average for the past 200 days is CAD 4.81, placing the current price just above this long‑term support level. The all‑time high for Medexus reached CAD 5.50 on 12 August 2026, while the 52‑week low fell to CAD 2.51 on 20 November 2025, underscoring the volatility inherent in the pharmaceutical sector.
Peer Performance Snapshot
Medexus’ performance can be contextualised by examining the recent movements of several related stocks:
| Stock | Symbol | Change (24 h) | Current Price (CAD) | Market Capitalisation (CAD million) |
|---|---|---|---|---|
| Big Ridge Gold | BRAU.V | –3.85 % | 0.52 | 181.5 |
| Cardiol Therapeutics | CRDL.TO | –0.63 % | 1.63 | 181.1 |
| Surge Copper | SURG.V | 0 % | 0.44 | 179.0 |
| Aftermath Silver | AAG.V | 0 % | 0.48 | 182.6 |
| Hydreight | NURS.V | –1.18 % | 3.22 | 182.0 |
While the broader market exhibits a mix of flat and slightly negative moves, Medexus remains comparatively stable, a fact that may appeal to investors seeking steadiness within the health‑care niche.
Company Overview
Medexus Pharmaceuticals Inc. is a Canadian‑based biopharmaceutical company focused on therapeutic areas that include rheumatology, autoimmune disease, specialty oncology, and pediatrics. Headquartered in Verdun, the company operates across North America and Canada. Medexus is listed on the Toronto Stock Exchange and continues to advance its pipeline of innovative treatments aimed at improving patient outcomes. Further details about the company’s research, product portfolio, and corporate governance can be found on its website at www.medexus.com .
